SMTL ID : 6omu.1

Structure of human Bruton's Tyrosine Kinase in complex with Evobrutinib

Coordinates

PDB Format

Method

X-RAY DIFFRACTION 1.41 Å

Oligo State

monomer

Ligands

1 x CL: CHLORIDE ION(Non-functional Binders)

CL.1: 5 residues within 4Å: Chain A: Y.88, M.89, A.90, N.142, D.143 Ligand excluded by PLIP

1 x MZJ: 1-[4-({[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}methyl)piperidin-1-yl]prop-2-en-1-one(Non-covalent)

MZJ.2: 15 residues within 4Å: Chain A: L.20, V.28, A.40, K.42, M.61, T.86, E.87, M.89, C.93, N.96, R.137, L.140, S.150, D.151, F.152 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:K.42, A:L.140 Hydrogen bonds: A:E.87, A:M.89, A:N.96 Water bridges: A:C.93 pi-Stacking: A:F.152

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Caldwell, R.D. et al., Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J.Med.Chem. (2019)

Release Date

2019-08-14

Peptides

Tyrosine-protein kinase BTK: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
A

Tyrosine-protein kinase BTK

Related Entries With Identical Sequence